Street Calls of the Week
SAN DIEGO - Avidity Biosciences, Inc. (NASDAQ:RNA), currently valued at $5.8 billion and showing a strong 54% gain year-to-date according to InvestingPro, announced Monday it has closed its previously announced public offering, raising $690 million in gross proceeds through the sale of 17.25 million shares of common stock at $40 per share.
The offering included the full exercise of the underwriters’ option to purchase an additional 2.25 million shares. All shares in the offering were sold by the company. Analysts remain bullish on RNA’s prospects, with price targets ranging from $52 to $96 per share, as revealed by InvestingPro data.
Avidity plans to use the net proceeds to advance its three late-stage clinical programs focused on rare muscle diseases, build commercial inventory for potential product launches, expand its commercial infrastructure, and further develop its Antibody Oligonucleotide Conjugates (AOCs) platform technology. The company maintains a strong financial position with a healthy current ratio of 9.26 and minimal debt on its balance sheet, according to InvestingPro analysis.
The biopharmaceutical company is developing AOCs, which combine monoclonal antibodies with oligonucleotide therapies, targeting rare muscle diseases including myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy.
Leerink Partners, J.P. Morgan, TD Cowen, Cantor and Wells Fargo Securities acted as joint bookrunning managers for the offering.
The securities were offered pursuant to a shelf registration statement that became automatically effective upon filing with the Securities and Exchange Commission, according to the company’s press release statement.
In other recent news, Avidity Biosciences has been active with several significant developments. The company has priced an upsized public offering of 15 million shares at $40.00 per share, expected to generate approximately $600 million in gross proceeds. This follows an earlier announcement of a $500 million public stock offering intended to support its late-stage clinical programs and expand its infrastructure. Meanwhile, H.C. Wainwright has raised its price target for Avidity Biosciences to $87, maintaining a Buy rating based on positive data from the EXPLORE44 and EXPLORE44-OLE studies on Duchenne muscular dystrophy (DMD). Similarly, BofA Securities increased its price target to $65 after the company’s recent stock offering and positive DMD data. TD Cowen also reiterated a Buy rating with a $78 price target, highlighting compelling improvements in DMD patients from the EXPLORE44-OLE trial. These developments reflect ongoing confidence in Avidity Biosciences’ research and market strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.